Comparing two schedules of high-dose dexamethasone for newly diagnosed ITP
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial compares two different dosing schedules of a high-dose corticosteroid called dexamethasone to see which one works better for people who have just been diagnosed with ITP (when your immune system attacks your platelets, causing low counts and bleeding). The goal is to find a treatment that raises your platelet count more effectively and safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have been recently diagnosed with immune thrombocytopenia (ITP), a condition where your immune system destroys platelets, and your platelet count is very low (below 30) or you have bleeding symptoms.
- Your low platelets must not be caused by another illness, like leukemia, lupus, or thyroid disease, or by certain medications (such as blood thinners or some antibiotics).
- You must not have had a stroke, heart attack, or blood clot in the past 6 months, and you must not need blood thinners.
- You must not have severe kidney or liver problems, active infections (like HIV, hepatitis B or C), or a history of cancer.
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a drug called orelabrutinib to high-dose dexamethasone (a steroid) works better than dexamethasone alone for treating newly diagnosed immune thrombocytopenia (ITP)—a condition where your body destroys its own platelets, causing very low blood counts. The goal is to see if the combination helps raise your platelet count and prevents bleeding.
This study tests an investigational drug called DZD8586 for people with long-term ITP (low platelets) that hasn't improved with standard treatments. The goal is to see if it can safely raise platelet counts and reduce bleeding risk.
This Phase 3 study compares two ways of treating immune thrombocytopenia (ITP) to raise blood platelet counts and reduce bleeding. It tests whether IgG given through a vein plus prednisone works better (or safer) than high-dose dexamethasone.
This trial tests the combination of upadacitinib (an immune-modulating drug) and high-dose dexamethasone (a steroid) as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). The goal is to see if this combination can raise your platelet count and reduce bleeding better than usual care.
This trial tests if adding hydroxychloroquine (HCQ) to the steroid dexamethasone (DEX) works better than dexamethasone alone for adults with immune thrombocytopenia (ITP) who have a positive antinuclear antibody (ANA) blood test. The goal is to see if this combination can safely raise platelet counts and reduce bleeding risk.
This study tests a combination of multiple drugs given in sequence to adults with newly diagnosed immune thrombocytopenia (ITP), a condition of low platelets. The goal is to see if this approach improves platelet counts and is safe.
Hear when a new Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.